1039phealth Economic Analysis of the Randomized Multicenter Phase Ii Trial Sakk 77/08: Sorafenib with or without Everolimus in Patients with Unresectable Hepatocellular Carcinoma (hcc).
نویسندگان
چکیده
K. Matter-Walstra1, M. Schwenkglenks1, Q. Li2, I. Cvijetic3, B. Tschanz3, P. Samaras4, P. Saletti5, A.D. Roth6, D. Horber7, D. Koeberle7 Institute of Pharmaceutical Medicine, University Basel, Basel, SWITZERLAND Statistics, SAKK, Bern, SWITZERLAND Clinical Trial Management, SAKK, Bern, SWITZERLAND Inner Medicine, University Hospital Zürich, Zürich, SWITZERLAND Oncology, Istituto Oncologico della Svizzera Italiana, Bellinzona, SWITZERLAND Oncology, University Hospitals of Geneva, Geneva, SWITZERLAND Dept. Oncology/hematology, Kantonsspital St. Gallen, St. Gallen, SWITZERLAND
منابع مشابه
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival...
متن کاملA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival...
متن کاملA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival...
متن کاملA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib.
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival...
متن کاملA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
The SHARP study in 2007 [1] and the Asia Pacific study in 2008 [2] led to the worldwide approval of sorafenib as the standard therapy for unresectable hepatocellular carcinoma (HCC). However, clinical trials investigating sunitinib [3] , brivanib [4] , and linifanib [5] as first-line treatments, with sorafenib as a control arm, failed to meet their primary endpoint of improving overall survival...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 25 suppl_4 شماره
صفحات -
تاریخ انتشار 2014